Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Summary of Financial Statements for the Three Months Ended June 30, 2026 [IFRS] (Consolidated)

August 5, 2026

Company name: JMDC Inc.
Listing: Tokyo Stock Exchange
Stock code: 4483
URL: https://www.jmdc.co.jp/en/
Representative: Ryo Noguchi, President and CEO
Inquiries: Makoto Ohashi, Executive Officer and CFO
TEL: +81-3-5733-5010

Scheduled date to commence dividend payments: –
Preparation of supplementary material on financial results: Yes
Holding of financial results presentation meeting: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the first three months of the fiscal year ending March 31, 2027 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	12,605	17.5	1,823	17.5	1,688	17.1	1,132	18.3
June 30, 2025	10,725	32.5	1,552	48.8	1,441	40.6	957	31.1

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Three months ended	Millions of yen	%	Millions of yen	%	Yen	Yen
June 30, 2026	1,131	17.0	1,026	(2.2)	17.28	17.14
June 30, 2025	966	32.8	1,049	43.5	14.79	14.65

Reference: EBITDA Three months ended June 30, 2026 ¥2,663 million [17.4%]
Three months ended June 30, 2025 ¥2,267 million [37.5%]

Note: EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent
As of	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2026	154,056	83,205	83,063	53.9
March 31, 2026	158,538	84,183	83,677	52.8

2. Cash dividends

	Annual dividends				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	–	0.00	–	18.00	18.00
Fiscal year ending March 31, 2027	–				
Fiscal year ending March 31, 2027 (Forecast)		–	–	–	–

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated earnings forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30, 2026 (cumulative)	27,100	17.4	4,500	11.8	4,100	12.1	2,700	15.2	2,650	11.5	40.49
Fiscal year ending March 31, 2027	60,500	19.9	11,500	9.3	11,000	10.4	7,200	5.7	7,100	4.9	108.19

Note: Revisions to the earnings forecasts most recently announced: Yes

For details, please refer to “1. Outline of business performance (3) Explanation of consolidated earnings forecasts and other forward-looking statements” on pages 4 to 5 of the attached materials.

Reference: EBITDA Six months ending September 30, 2026 (cumulative) ¥6,100 million [10.4%]

Fiscal year ending March 31, 2027 ¥15,000 million [13.8%]

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at end of the period (including treasury shares)

As of June 30, 2026	65,446,208 shares
As of March 31, 2026	65,439,808 shares

(ii) Number of treasury shares at end of the period

As of June 30, 2026	816 shares
As of March 31, 2026	816 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

For the three months ended June 30, 2026	65,440,517 shares
For the three months ended June 30, 2025	65,374,756 shares

*** Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit corporation: None**

*** Proper use of earnings forecasts, and other special items**

Notes on forward-looking statements

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual business and other results may differ substantially due to various factors. For details regarding matters related to earnings forecasts, please refer to pages 4 to 5 of the attached materials.

How to obtain supplementary documents on financial results

Supplementary documents on financial results are released via TDnet on the same day.

Attached Material Index

1. Outline of business performance 2
(1) Outline of business performance for the three months ended June 30, 2026 2
(2) Outline of financial position for the three months ended June 30, 2026 4
(3) Explanation of consolidated earnings forecasts and other forward-looking statements 4
2. Condensed quarterly consolidated financial statements and significant notes thereto 6
(1) Condensed quarterly consolidated statement of financial position 6
(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income 7
(3) Condensed quarterly consolidated statement of changes in equity 9
(4) Condensed quarterly consolidated statement of cash flows 11
(5) Notes to condensed quarterly consolidated financial statements 12
Notes on going concern assumption 12
Segment information 12
Significant subsequent events 13

1. Outline of business performance

(1) Outline of business performance for the three months ended June 30, 2026

JMDC Inc. (the "Company") is promoting the health of citizens, and delivering increased value of medical service providers and helping optimize their operations through gathering diverse data on the Japanese healthcare industry and thus benefiting society, with the aim of realizing a sustainable healthcare system by leveraging data and ICT.

In the Healthcare-Big Data segment, to promote the health services for payers, centered on health insurance unions, we provide analysis services for data held by payers as well as personal health record (PHR) services developed by the Company. We also provide services such as medical data analysis and medical factoring to medical institutions as well as medicine databases. Furthermore, we have created a database of anonymously processed information in the course of pursuing this business and are promoting scientific and industrial applications of this data.

In the Tele-medicine segment, we provide a matching service that connects medical institutions lacking a sufficient number of radiologists with contracted radiologists using a remote image interpretation system, as well as an ASP service that connects medical institutions with radiologists via the cloud to enable remote diagnostic imaging.

Operating results for the three months ended June 30, 2026 are as follows.

(Operating results)

(Millions of yen)

Category	13th fiscal year Three months ended June 30, 2025	14th fiscal year Three months ended June 30, 2026	YoY change	
Revenue	10,725	12,605	1,880	17.5%
Operating profit	1,552	1,823	271	17.5%
EBITDA [margin]	2,267 [21.1%]	2,663 [21.1%]	395	17.4%

(Segment results)

(Millions of yen)

Category		13th fiscal year Three months ended June 30, 2025	14th fiscal year Three months ended June 30, 2026	YoY change	
Healthcare-Big Data	Segment revenue	9,201	10,955	1,754	19.1%
	Segment profit [ratio]	1,919 [20.9%]	2,250 [20.5%]	330	17.2%
Tele-medicine	Segment revenue	1,524	1,649	125	8.2%
	Segment profit [ratio]	536 [35.2%]	653 [39.6%]	117	21.9%
Adjustment	Segment revenue	–	–	–	–
	Segment profit	(187)	(240)	(52)	–
Total	Revenue	10,725	12,605	1,880	17.5%
	EBITDA [margin]	2,267 [21.1%]	2,663 [21.1%]	395	17.4%

(Note) EBITDA is an objective indicator for judging the achievement of the JMDC Group's (the "Group's") management policies and strategies or management objectives. The Group uses EBITDA to measure the performance of each segment and believes that it is a useful and necessary measure to assess the Group's performance more effectively. The formulas for calculating EBITDA and EBITDA margin are as follows.

- EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
- EBITDA margin: EBITDA / Revenue x 100

Results by each segment are as follows.

Healthcare-Big Data

The Group possesses the largest scale of healthcare big data in Japan that is available for public through data anonymization of receipts (admitted patients, day patients, prescriptions), medical examinations and member records received from health insurance unions, etc. During the three months ended June 30, 2026, the number of contracted health insurance unions, etc. increased year-on-year. The annual transaction value at pharmaceutical and insurance companies, etc. which use and utilize the healthcare big data, showed robust results. The business is continuing to expand.

Moreover, the Pep Up health information platform developed by the Company is used to generate individualized advice and display risk of diseases for every individual user based on the above healthcare-big data. The number of IDs issued for Pep Up continued to expand during the three months ended June 30, 2026.

As a result, segment revenue for the three months ended June 30, 2026 was ¥10,955 million and segment profit (segment EBITDA) was ¥2,250 million.

Tele-medicine

The Group has the biggest platform for radiologists in Japan. In the three months ended June 30, 2026, revenue increased on a year-on-year basis as a result of the continued increase in the number of medical institutions utilizing remote image interpretation services.

We continue to take measures to expand our business, including adding functions to “AI-RAD,” an artificial intelligence engine platform that assists in diagnostic imaging, and preparations for full-scale business development in Asia.

As a result, segment revenue for the three months ended June 30, 2026 was ¥1,649 million and segment profit (segment EBITDA) was ¥653 million.

(Reconciliation of EBITDA to operating profit)

(Millions of yen)

	13th fiscal year Three months ended June 30, 2025	14th fiscal year Three months ended June 30, 2026
EBITDA	2,267	2,663
Depreciation and amortization	(740)	(879)
Other income	32	58
Other expenses	(7)	(17)
Operating profit	1,552	1,823

(2) Outline of financial position for the three months ended June 30, 2026

(i) Assets, liabilities and equity

Assets

Assets at the end of the first quarter under review were ¥154,056 million, a decrease of ¥4,481 million compared with the end of the fiscal year ended March 31, 2026. The main changes were a decrease of ¥8,109 million in trade and other receivables, despite increases of ¥1,830 million in cash and cash equivalents, ¥840 million in contract assets, and ¥300 million in other current assets. For details regarding the changes in cash and cash equivalents, please refer to "(ii) Cash flows."

Liabilities

Liabilities at the end of the first quarter under review were ¥70,851 million, a decrease of ¥3,503 million compared with the end of the fiscal year ended March 31, 2026. This was mainly due to decreases of ¥1,541 million in trade and other payables, ¥1,063 million in income taxes payable due to payment, and ¥995 million in borrowings in current liabilities.

Equity

Equity at the end of the first quarter under review was ¥83,205 million, a decrease of ¥978 million compared with the end of the fiscal year ended March 31, 2026. This was mainly due to the recording of ¥1,177 million in dividend payment, ¥1,132 million in profit, and ¥833 million in transactions with non-controlling interests.

(ii) Cash flows

Cash and cash equivalents ("net cash") at the end of the first quarter under review was ¥30,780 million, an increase of ¥1,830 million compared with the end of the fiscal year ended March 31, 2026.

The respective cash flow positions for the three months ended June 30, 2026, and the factors thereof are as follows.

Cash flows from operating activities

Net cash provided by operating activities was ¥6,221 million (¥5,372 million provided in the three months ended June 30, 2025). This was mainly due to the recording of ¥1,688 million in profit before tax and a decrease of ¥8,111 million in trade and other receivables, despite recording a decrease of ¥1,554 million in trade and other payables and ¥1,443 million in income taxes paid.

Cash flows from investing activities

Net cash used in investing activities was ¥968 million (¥5,138 million used in the three months ended June 30, 2025). This was mainly due to purchase of intangible assets of ¥436 million, purchase of property, plant and equipment of ¥195 million, and payments for loans receivable of ¥136 million.

Cash flows from financing activities

Net cash used in financing activities was ¥3,422 million (¥3,225 million provided in the three months ended June 30, 2025). This was mainly due to the recording of ¥2,037 million in repayments of long-term borrowings and ¥1,175 million in dividends paid.

(3) Explanation of consolidated earnings forecasts and other forward-looking statements

The consolidated earnings forecasts for the fiscal year ending March 31, 2027 are unchanged from the forecasts announced on May 8, 2026. However, as shown below, the Company has decided to announce the consolidated earnings forecasts for the six months ending September 30, 2026. Because of how the Group's business is constructed, its consolidated earnings are concentrated in the second half of the fiscal year, which makes it difficult to provide a forecast for the first half of the fiscal year. Accordingly, the Company has a policy not to announce the earnings forecasts for the first six-month period. Nevertheless, because of the smooth progress of the business environment, which has enhanced

our visibility of the first half of the fiscal year, the Company has decided to disclose an earnings forecast for the first six-month period.

	Revenue	Operating profit	Profit before tax	Profit	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previously announced forecast (A)	–	–	–	–	–	–
Revised forecast (B)	27,100	4,500	4,100	2,700	2,650	40.49
Increase (Decrease) (B-A)	–	–	–	–	–	–
Increase (Decrease) percentage (%)	–	–	–	–	–	–
(Reference) Actual results for the six months ended September 30, 2025	23,080	4,025	3,657	2,343	2,376	36.35

2. Condensed quarterly consolidated financial statements and significant notes thereto

(1) Condensed quarterly consolidated statement of financial position

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	28,950	30,780
Trade and other receivables	24,015	15,905
Contract assets	50	890
Other financial assets	1,880	2,017
Inventories	505	658
Other current assets	1,165	1,466
Total current assets	56,568	51,718
Non-current assets		
Property, plant and equipment	20,932	20,965
Goodwill	62,569	62,583
Intangible assets	6,012	6,122
Other financial assets	10,508	10,351
Deferred tax assets	1,712	1,764
Other non-current assets	235	549
Total non-current assets	101,970	102,337
Total assets	158,538	154,056
Liabilities and equity		
Liabilities		
Current liabilities		
Borrowings	5,557	4,561
Trade and other payables	11,542	10,001
Lease liabilities	1,475	1,534
Income taxes payable	1,635	572
Contract liabilities	1,477	1,771
Other current liabilities	3,198	2,930
Total current liabilities	24,887	21,371
Non-current liabilities		
Borrowings	35,941	35,879
Lease liabilities	9,073	9,053
Retirement benefit liability	422	510
Provisions	826	864
Deferred tax liabilities	2,357	2,341
Contract liabilities	586	576
Other non-current liabilities	259	253
Total non-current liabilities	49,468	49,479
Total liabilities	74,355	70,851
Equity		
Share capital	25,167	25,171
Capital surplus	28,175	27,711
Treasury shares	(3)	(3)
Other components of equity	30	28
Retained earnings	30,307	30,155
Total equity attributable to owners of parent	83,677	83,063
Non-controlling interests	505	141
Total equity	84,183	83,205
Total liabilities and equity	158,538	154,056

(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income

Condensed quarterly consolidated statement of profit or loss

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Revenue	10,725	12,605
Cost of sales	5,224	5,859
Gross profit	5,500	6,745
Selling, general and administrative expenses	3,973	4,962
Other income	32	58
Other expenses	7	17
Operating profit	1,552	1,823
Finance income	0	15
Finance costs	111	151
Share of profit of investments accounted for using equity method	0	0
Profit before tax	1,441	1,688
Income tax expense	484	555
Profit	957	1,132
Profit attributable to		
Owners of parent	966	1,131
Non-controlling interests	(9)	1
Profit	957	1,132
Earnings per share		
Basic earnings per share (Yen)	14.79	17.28
Diluted earnings per share (Yen)	14.65	17.14

Condensed quarterly consolidated statement of comprehensive income

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit	957	1,132
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	91	(104)
Total of items that will not be reclassified to profit or loss	91	(104)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	0	(1)
Total of items that may be reclassified to profit or loss	0	(1)
Other comprehensive income, net of tax	92	(106)
Comprehensive income	1,049	1,026
Comprehensive income attributable to		
Owners of parent	1,058	1,024
Non-controlling interests	(9)	1
Comprehensive income	1,049	1,026

(3) Condensed quarterly consolidated statement of changes in equity

Three months ended June 30, 2025 (from April 1 to June 30, 2025)

(Millions of yen)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2025	25,134	28,227	(3)	(5)	–	33
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	0	91	–
Total comprehensive income	–	–	–	0	91	–
Exercise of share acquisition rights	6	6	–	–	–	(0)
Dividends	–	–	–	–	–	–
Transfer to retained earnings	–	–	–	–	(91)	–
Total transactions with owners	6	6	–	–	(91)	(0)
Balance as of June 30, 2025	25,140	28,233	(3)	(5)	–	33

	Equity attributable to owners of parent			Non-controlling interests	Total
	Other components of equity	Retained earnings	Total		
	Total				
Balance as of April 1, 2025	27	24,634	78,022	453	78,475
Profit	–	966	966	(9)	957
Other comprehensive income	92	–	92	–	92
Total comprehensive income	92	966	1,058	(9)	1,049
Exercise of share acquisition rights	(0)	–	11	–	11
Dividends	–	(1,045)	(1,045)	–	(1,045)
Transfer to retained earnings	(91)	91	–	–	–
Total transactions with owners	(91)	(954)	(1,034)	–	(1,034)
Balance as of June 30, 2025	28	24,646	78,046	444	78,491

Three months ended June 30, 2026 (from April 1 to June 30, 2026)

(Millions of yen)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2026	25,167	28,175	(3)	(10)	–	40
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	(1)	(104)	–
Total comprehensive income	–	–	–	(1)	(104)	–
Exercise of share acquisition rights	3	3	–	–	–	(0)
Forfeiture of share acquisition rights	–	0	–	–	–	(0)
Dividends	–	–	–	–	–	–
Transactions with non-controlling interests	–	(468)	–	–	–	–
Transfer to retained earnings	–	–	–	–	104	–
Total transactions with owners	3	(463)	–	–	104	(0)
Balance as of June 30, 2026	25,171	27,711	(3)	(11)	–	40

	Equity attributable to owners of parent			Non-controlling interests	Total
	Other components of equity	Retained earnings	Total		
	Total				
Balance as of April 1, 2026	30	30,307	83,677	505	84,183
Profit	–	1,131	1,131	1	1,132
Other comprehensive income	(106)	–	(106)	–	(106)
Total comprehensive income	(106)	1,131	1,024	1	1,026
Exercise of share acquisition rights	(0)	–	7	–	7
Forfeiture of share acquisition rights	(0)	–	–	–	–
Dividends	–	(1,177)	(1,177)	–	(1,177)
Transactions with non-controlling interests	–	–	(468)	(365)	(833)
Transfer to retained earnings	104	(104)	–	–	–
Total transactions with owners	104	(1,282)	(1,638)	(365)	(2,004)
Balance as of June 30, 2026	28	30,155	83,063	141	83,205

(4) Condensed quarterly consolidated statement of cash flows

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit before tax	1,441	1,688
Depreciation and amortization	740	879
Decrease (increase) in trade and other receivables	5,963	8,111
Decrease (increase) in contract assets	(790)	(840)
Decrease (increase) in inventories	(83)	(152)
Increase (decrease) in trade and other payables	948	(1,554)
Increase (decrease) in contract liabilities	(26)	282
Other	(501)	(630)
Subtotal	7,693	7,783
Interest and dividends received	0	12
Interest paid	(90)	(131)
Income taxes paid	(2,231)	(1,443)
Net cash provided by (used in) operating activities	5,372	6,221
Cash flows from investing activities		
Purchase of property, plant and equipment	(50)	(195)
Purchase of intangible assets	(342)	(436)
Payments for loans receivable	(100)	(136)
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(4,530)	(22)
Other	(115)	(177)
Net cash provided by (used in) investing activities	(5,138)	(968)
Cash flows from financing activities		
Proceeds from long-term borrowings	5,500	980
Repayments of long-term borrowings	(943)	(2,037)
Repayments of lease liabilities	(299)	(362)
Proceeds from exercise of share acquisition rights	11	7
Dividends paid	(1,043)	(1,175)
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	–	(833)
Net cash provided by (used in) financing activities	3,225	(3,422)
Net increase (decrease) in cash and cash equivalents	3,458	1,829
Cash and cash equivalents at beginning of period	32,176	28,950
Effect of exchange rate changes on cash and cash equivalents	(0)	0
Cash and cash equivalents at end of period	35,634	30,780

(5) Notes to condensed quarterly consolidated financial statements

Notes on going concern assumption

Not applicable.

Segment information

(1) Overview of reportable segments

The Group's reportable segments are components of the Group for which discrete financial information is available, and whose operating results are regularly reviewed by the Board of Directors to make decisions about managerial resources to be allocated to the segments and assess their performances. The Group considers similarities in the nature of the services it provides and has reportable segments: "Healthcare-Big Data" and "Tele-medicine."

The main businesses and main services included in each reportable segment are as follows.

Reportable segments	Main businesses	Main services
Healthcare-Big Data	Business for industry Business for payers and individuals Business for medical service providers	Development and provision of medical databases (receipts, pharmaceuticals, etc.) and analysis of medical big data
Tele-medicine	Tele-medicine business	Remote image interpretation matching service and ASP service for remote image interpretation system

(2) Information about reportable segments

Revenue and operating results by reportable segments of the Group are as follows.

Intersegment revenues are based on negotiated transaction prices, taking into account market prices and production costs. Segment profits are EBITDA (Operating profit + Depreciation and amortization ± Other income and/or expenses).

Three months ended June 30, 2025 (from April 1 to June 30, 2025)

(Millions of yen)

	Reportable segments			Adjustments (Note)	Consolidated
	Healthcare-Big Data	Tele-medicine	Total		
Revenue					
Revenue from external customers	9,201	1,524	10,725	–	10,725
Intersegment revenue	–	–	–	–	–
Total	9,201	1,524	10,725	–	10,725
Segment profit EBITDA	1,919	536	2,455	(187)	2,267

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

Three months ended June 30, 2026 (from April 1 to June 30, 2026)

(Millions of yen)

	Reportable segments			Adjustments (Note)	Consolidated
	Healthcare-Big Data	Tele-medicine	Total		
Revenue					
Revenue from external customers	10,955	1,649	12,605	–	12,605
Intersegment revenue	–	–	–	–	–
Total	10,955	1,649	12,605	–	12,605
Segment profit EBITDA	2,250	653	2,903	(240)	2,663

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

A reconciliation of EBITDA to profit before tax is as follows.

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
EBITDA	2,267	2,663
Depreciation and amortization	(740)	(879)
Other income	32	58
Other expenses	(7)	(17)
Operating profit	1,552	1,823
Finance income	0	15
Finance costs	(111)	(151)
Share of profit of investments accounted for using equity method	0	0
Profit before tax	1,441	1,688

Significant subsequent events

Not applicable.